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Abstract
Background: Thrombospondin1 (THBS1), cystene-rich protein 61 (Cyr61) and connective tissue
growth factor (CTGF) are all involved in the transforming growth factor-beta (TGF-β) signal
pathway, which plays an important role in the tumorigenesis. The purpose of this study is to
explore the expression and prognostic significance of these proteins in esophageal squamous cell
carcinoma (ESCC).
Methods: We used immunohistochemistry and western blotting to examine the expression status
of THBS1, Cyr61 and CTGF in ESCC. Correlations of THBS1, Cyr61 and CTGF over-expressions
with various clinicopathologic factors were also determined by using the Chi-square test or Fisher's
exact probability test. Survival analysis was assessed by the Kaplan-Meier analysis and the log-rank
test. Relative risk was evaluated by the multivariate Cox proportional hazards model.
Results: THBS1, Cyr61 and CTGF were all over-expressed in ESCC. THBS1 over-expression was
significantly associated with TNM stage (P = 0.029) and regional lymph node involvement (P =
0.026). Kaplan-Meier survival analysis showed that over-expression of THBS1, Cyr61 or CTGF was
related to poor survival of ESCC patients (P = 0.042, P = 0.020, P = 0.018, respectively). Multivariate
Cox analysis demonstrated that Cyr61 and CTGF were independent factors in prognosis of ESCC.
Conclusion: Cyr61, CTGF and THBS1 were all over-expressed in ESCC and might be new
molecular markers to predict the prognosis of ESCC patients.
Background
Esophageal squamous cell carcinoma (ESCC) is the fourth
most common malignancy in China, even prevalent
throughout the world, with high mortality rate [1]. Diag-
nosis of ESCC at its early stage still remains difficult and
advanced ESCC frequently displays local invasion and
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lymph node metastasis, which is one of the important rea-
sons for its poor prognosis [2]. The development of this
malignancy rises from the stepwise accumulations of mul-
tiple genetic alterations, leading to the activation of onco-
genes and/or the inactivation of tumor suppressor genes.
Transforming growth factor-beta (TGF-β) is both a tumor
suppressor and tumor oncogene [3]. Early in carcinogen-
esis it acts as a tumor suppressor but later it acts as a stim-
ulator of tumor invasion by prompting extracellular
matrix production and angiogenesis, stimulating tumor
proliferation, and inhibiting host immune functions [4-
6]. TGF-β signaling pathway can be activated by
thrombospondin1 (THBS1) through its interaction with
latent TGF-β binding proteins (LTBP) so that TGF-β is
capable of binding to its receptors and stimulating the
Smad pathway [7,8]. Smad proteins are able to bind to
cystene-rich protein 61 (Cyr61) and connective tissue
growth factor (CTGF) promoters, which leads to transcrip-
tion of Cyr61 and CTGF and activation of angiogenesis
and tumor growth [9,10].
Depending on the cell type, THBS1, CTGF and Cyr61 may
have both negative and positive effect on tumor progres-
sion [11,12]. It has been reported that THBS1 expression
in the stroma of ESCC was correlated with lymph node
metastasis and Cyr61 expression in Barrett's tissue of
esophageal adenocarcinoma was significantly higher than
that in Barrett's esophageal tissue with no sign of cancer
[13,14]. Recently, CTGF expression was found to be up-
regulated in ESCC and significantly related to survival of
ESCC patients [15,16]. However, the expressions and the
prognostic significances of Cyr61 and THBS1 in ESCC still
remain uncertain.
To further explore the expression patterns of THBS1,
Cyr61 and CTGF and determine whether these proteins
could be prognostic factors in ESCC, we investigated their
expressions in a series of ESCC by using immunohisto-
chemistry staining and western blotting. Furthermore, the
correlations of these proteins with survival of ESCC
patients were also addressed.
Methods
Patient selection
Eighty surgically removed ESCC samples (complete
tumor resection, R0) embedded in paraffin wax blocks
and thirty-eight cases of para-cancerous epithelium, col-
lected between 1997 and 2006, were retrieved from the
Department of Clinical Pathology at Center Hospital of
Shantou City, Tumor Hospital of Shantou University
Medical College and the Second Affiliated Hospital of
Shantou University Medical College. The cases (only sur-
gery) were selected in this study if a follow-up was
obtained and clinical data were available. This study was
approved by the ethical committee of the Center Hospital
of Shantou City, the ethical committee of Tumor Hospital
of Shantou University Medical College and the ethical
committee of the Second Affiliated Hospital of Shantou
University Medical College. The mean age of the patients
was 57 years (range: 36–75). These paraffin blocks had
undergone TMA construction before immunostaining.
Paraffin sections were directly subjected to pathological
staining and immunohistochemistry. At the end of the
follow-up period there were no surviving patients.
Construction of tissue microarrays
The construction of esophageal carcinoma tissue microar-
ray was performed as described before [17]. Briefly, repre-
sentative regions of each tissue were selected from
hematoxylin- and eosin-stained sections and marked on
the individual paraffin blocks. Samples were chosen from
those specimens with more tissue available, so that correl-
ative studies would not be compromised. Two tissue cores
were obtained from each specimen, measuring 1.8 mm in
diameter and ranging in length from 1.0 to 3.0 mm
depending on the depth of tissue in the donor block. Each
core was precisely arrayed into a new paraffin block. These
microarrays were serially sectioned (4 μm), and stained
with hematoxylin and eosin to verify tissue sampling and
completeness. The unstained sections were baked over-
night at 56°C in preparation for immunohistochemistry.
Immunohistochemical evaluation
Mouse monoclonal CTGF antibody (1:100 dilution in
PBS containing 0.01% Triton X-100, R&D Systems, USA),
rabbit polyclonal Cyr61 antibody (1:100 dilution, Novus
Biologicals) and mouse monoclonal THBS1 antibody
(1:20 dilution, R&D Systems) were used in this study. The
superPicTure Polymer Detection Kit and the Liquid DAB
Substrate Kit (Zymed/Invitrogen) were used to carry out
the immunohistochemical studies. Briefly, slides were
submerged in a Peroxidase Quenching Solution, contain-
ing 1 part of 30% hydrogen peroxide to 9 parts of absolute
methanol, for 10 minutes and were then washed with
PBS. Then, 100 μl of serum blocking solution was added
to each section, followed by incubation for 10 min and
then draining the solution. At this time, 100 μl of the
appropriate antibodies were applied to each section, and
the slides were incubated in a moist chamber for 30 min,
followed by a rinse with PBS. After rinsing, 100 μl of HRP
Polymer Conjugate was applied to each section, and incu-
bated for 10 min, followed by a rinse with PBS. Finally,
100 μl of DAB chromogen was applied to each section and
incubated for 3–10 min. Samples were then rinsed well
with distilled water. Subsequently, slides were counter-
stained with Maye's hematoxylin, dehydrated, and
mounted. The negative controls were prepared by substi-
tuting PBS for the primary antibodies.BMC Cancer 2009, 9:291 http://www.biomedcentral.com/1471-2407/9/291
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Staining of the cores was scored based on signal intensity
(0–3) and the percentage of positive cells (0 ≤ 10%, 1 =
10–25%, 2 = 25–50%, and 3 ≥ 50%). Over-expressions of
THBS1, Cyr61 and CTGF were arbitrarily defined as more
than 25% of cells with strong staining (score 2 and 3).
Input from visual inspection data and detection of events
in digitized images was stored in dedicated tables for com-
parison and statistical analysis. A disc was considered
unsuitable for analysis if it was completely absent, if it
contained no tumor tissue (sampling error), or if it con-
tained too few (<10%) tumor cells for analysis (unin-
formative). For each patient, the mean score of a
minimum of two core samples was calculated.
Western blotting analysis
Tissues were lysed in a RIPA buffer and the protein con-
centration was estimated by the Bradford method. Equal
amounts of tissue or cell lysates (50 μg) were electro-
phoresed on 10% polyacrylamide gel and transferred to
polyvinylidene difluoride membranes (Millipore). The
membraneswere then blocked with 5% skim milk-phos-
phate-buffered saline Tween (0.01 M PBS, 0.05% Tween
20) for 1 h and incubated at room temperature for 1 h
with the primary antibody as described above. The mem-
brane was subsequently incubated at room temperature
for 1 h with horse radish peroxidase-linked second anti-
body and analysed using western blotting Luminol Rea-
gent (Santa Cruz Biotechnology). Image acquisition and
quantitative analysis were carried out using the
FluorChem 8900 image analysis system (Alpha
Innotech).
Statistical analysis
Correlations of THBS1, Cyr61 and CTGF over-expressions
with the clinical and pathological variables including gen-
der, regional lymph node involvement, histological grade
and TNM stage were made using the Chi-square test or
Fisher's exact probability test. Survival was assessed by
Kaplan-Meier analysis with log-rank score for determining
statistical significance. Relative risk was evaluated by the
multivariate Cox proportional hazards model. Calcula-
tion and analysis were performed with SPSS for Windows
(Version 13.0) and where appropriate, was two tailed. P
value less than 0.05 was considered as statistically signifi-
cant.
Results
Clinical and pathological variable analysis
Samples from eighty patients who underwent primary
surgical resection for ESCC met inclusion criteria were
used to build tissue microarray. Of the esophageal squa-
mous cell carcinoma that met inclusion criteria, all were
Table 1: Comparison of Cyr61, CTGF and THBS1 immunohistochemisty wih clinicopathological features in patients with ESCC
THBS1† Cyr61† CTGF†
n-+ P n-+ P n-+ P
Age(years)
≤ 57 43 6 37 0.494 43 21 22 0.987 43 25 18 0.184
>57 37 3 34 37 18 19 37 16 21
Gender
Male 58 6 52 0.700 58 29 29 0.805 58 33 25 0.101
F e m a l e 2 2 31 9 2 21 01 2 2 2 81 4
Regional lymph node
N0 48 2 46 0.026* 48 23 25 0.855 48 27 21 0.273
N 1 3 2 72 5 3 21 61 6 3 21 41 8
Primary tumor
T 1 413 422 431
T 2 606 633 624
T3 64 7 57 0.479 64 30 34 0.868 64 34 30 0.501
T 4 615 642 624
Histologic grade
Well differentiated 24 1 23 24 11 13 24 11 13
Moderately differentiated 48 6 42 0.179 48 22 26 0.355 48 26 22 0.844
P o o r l y  d i f f e r e n t i a t e d 826 862 844
TNM Stage
I/IIa 45 1 44 45 21 24 45 26 19
IIb/III 35 8 27 0.009* 35 18 17 0.673 35 15 20 0.185
ESCC 8 0 87 2 8 03 94 1 8 04 13 9
Normal mucosa 38 31 7 0.000* 38 34 4 0.000* 38 30 8 0.004*
TNM: tumor node metastasis; †: (-) = nonoverexpressor; (+) = overexpressor.
*Significant at P < 0.05 level.BMC Cancer 2009, 9:291 http://www.biomedcentral.com/1471-2407/9/291
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interpretable for THBS1, Cyr61 and CTGF staining.
Demographic and clinicopathological variables for the
cohort were summarised in Table 1.
Expressions THBS1, Cyr61 and CTGF in ESCC
In ESCC, THBS1, Cyr61 and CTGF immunoreactivities all
displayed intense diffuse cytoplasmic staining (Figure 1A,
C and 1E). In contrast, these proteins just showed weak
staining in the basal and suprabasal proliferative layers of
normal epithelium (Figure 1B, D and 1F). Over-expres-
sion was defined as intense diffuse cytoplasmic staining in
>25% of tumor cells. Hence, 72/80, 41/80 and 39/80 for
THBS1, Cyr61 and CTGF were respectively designated as
over-expressions. In comparison with the staining in nor-
mal epithelial tissue, their over-expressions were all statis-
tically significant (P < 0.05). In addition, elevated levels of
CTGF and CYR61 protein were also found in human
ESCC tissues compared with the paired normal tissue
from the patients as shown by western blotting analysis
(Figure 2).
Correlations of THBS1, Cyr61 and CTGF expression with 
various clinicopathologic factors
To obtain a better understanding of the clinical signifi-
cance of THBS1, Cyr61 and CTGF expression in ESCC, we
correlated their expression with a series of clinicopatho-
logical.
As shown in Table 1, THBS1 over-expression was signifi-
cantly associated with TNM stage (P = 0.029) and regional
lymph node invasion (P = 0.026). No association was
found between THBS1 status and the other clinicopatho-
logical variables. For Cyr61 and CTGF, there was no asso-
ciation between their expressions and these
clinicopathological variables (Table 1).
Impact of THBS1, Cyr61 and CTGF expressions on the 
overall survival of ESCC patient
Survival analysis on single protein expression demon-
strated that THBS1, Cyr61 and CTGF over-expressions
were all associated with shorter survival (P = 0.042, P =
0.020 and P = 0.018, respectively) (Figure 3).
We also explore the impact of combined expression of
these genes (optional two or all three genes) on patient
survival. Results revealed that combined expression of the
three genes resulted in remarkable low survival. The more
genes over-expressed, the shorter survival presented (Fig-
ure 4A). Obviously, ESCC patients with two or three genes
over-expression had a shorter survival rate then patients
with single gene over-expression (Figure 4B).
Multivariate analysis for the prognostic value of THBS1, 
Cyr61 and CTGF expressions
Since THBS1, Cyr61 or CTGF expression was shown to
have significant impact on the overall survival of patients
with ESCC, we included the expressions of these genes in
further prognostic value analysis.
Using the Cox proportional hazards model, we performed
multivariate analysis to assess the independent predictive
value of THBS1, Cyr61 and CTGF expressions for overall
survival. The following prognostic variables were also
included TNM stage, invasion degree and histological
stage. Noticeably, CTGF and Cyr61 expression status
could be independent prognostic factors for ESCC
patients (P = 0.028, P = 0.009, respectively, Table 2 and 3)
but not THBS1 (Table 4).
Discussion and Conclusion
TGF-β signaling pathway is operative in some tumor cells
and can contribute to tumor invasion, survival, and
Expressions of THBS1, Cyr61 and CTGF in normal human  esophageal epithelium and ESCC Figure 1
Expressions of THBS1, Cyr61 and CTGF in normal 
human esophageal epithelium and ESCC. Staining of 
the three genes was performed as indicated in Materials and 
Methods. Scale bar represents 100 μm in the tissue core 
shown in panel A-F. THBS1 (A), Cyr61 (B) and CTGF (C) in 
ESCC demonstrated strong cytoplasmic staining which was 
scored as over-expression. THBS1 (B), Cyr61 (C) and CTGF 
(D) in normal esophageal epithelium showed weak or absent 
staining and were scored as non-overexpression.BMC Cancer 2009, 9:291 http://www.biomedcentral.com/1471-2407/9/291
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metastases [5]. In esophageal carcinoma, altered expres-
sion of TGF-β receptors, Smad2 and Smad4, was corre-
lated with tumor progression or poor prognosis [18].
Recent study also revealed that the TGF-β pathway was
disturbed in ESCC and the expression of TGF-β1 was up-
regulated, which might be responsible for the high inva-
sive ability of ESCC cells [19-21]. In this study, we further
explored the expression and prognostic significance of
Expressions of CTGF and CYR61 protein in four, randomly picked, paired ESCC samples were analyzed by western blotting Figure 2
Expressions of CTGF and CYR61 protein in four, randomly picked, paired ESCC samples were analyzed by 
western blotting. Signal intensities for the expression of p-ERK1/2 or p-Smad2/3 were quantified by densitometric scanning 
and normalized by internal control (β-actin). CTGF and CYR61 were expressed predominantly in ESCC tissues compared with 
the match normal tissues.
Kaplan-Meier estimates of the survival by THBS1 (A), Cyr61  (B) and CTGF (C) status Figure 3
Kaplan-Meier estimates of the survival by THBS1 
(A), Cyr61 (B) and CTGF (C) status. THBS1, Cyr61 and 
CTGF over-expressions all have significantly lower survival 
rates than their respective non-overexpression.
Kaplan-Meier estimates of the survival by the combined  expression of THBS1, Cyr61 and CTGF Figure 4
Kaplan-Meier estimates of the survival by the com-
bined expression of THBS1, Cyr61 and CTGF. (A) 
revealed that the more overexpressed genes, the shorter the 
patient survival. (B) showed that patients with fewer than 
two overexpressed genes had longer survival.BMC Cancer 2009, 9:291 http://www.biomedcentral.com/1471-2407/9/291
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three TGF-β-relative genes (THBS1, CTGF and Cyr61) in
ESCC.
Cyr61 and CTGF, both transcriptional targeted gene of
TGF-β pathway, are members of the CCN (Cyr61/CTGF/
NOV) family. The altered-expressions of CCN proteins
had been reported in a wide range of tumors such as
breast cancer, non-small lung cancer and glioma [22-25].
Studies also suggest that expression and role of the CCN
proteins is dependent on the tumor type in which they
interact with different cell surface receptors [11]. In the
present study, by employing immunostaining and west-
ern blotting analysis, we first confirmed the over-expres-
sion of CTGF in ESCC and also revealed that Cyr61 in
ESCC was markedly higher than that in normal esopha-
geal tissue. Furthermore, we showed that over-expression
of CTGF or Cyr61 was related to poor survival and Cyr61
and CTGF were independent prognostic factors in ESCC.
CTGF and Cyr61 were reportedly related to poor survival
of patients in several cancers such as lung cancer and
endometrial cancer [26,27]. In ESCC, however, a previous
study suggested that high CTGF mRNA levels in ESCC
were associated with longer survival, which seemed
inconsistent with our findings [16]. Possible explanation
for the above contradiction might be as follow: in their
study, the mRNA was extracted from the whole cancer tis-
sue which included mRNA of cancer cells as well as some
stromal cells; but in this study, we aimed directly at the
protein expression level of CTGF in the cancer cells. Study
for the more precise mechanism is underway.
The expression of THBS1 is capable of activating TGF-β
signal pathway, leading to transcription of Cyr61 and
CTGF [7,8]. Methylation-induced silencing of THBS1
expression correlated with impaired TGF-β signaling as
indicated by decreased Smad2 phosphorylation and
nuclear localization [28]. THBS1 up-expression has been
found in metastatic lesions of colon tumors and osteosar-
coma and was significantly associated with overall sur-
vival in bladder cancer and lymph node metastasis in
gallbladder adenocarcinoma [29-31]. Recently, it is
reported that loss of THBS1 expression was also signifi-
cantly associated with distal location, vascular invasion
and distant metastasis in gastric cancer and with unfa-
vourable histological grade and shorter overall survival in
penile squamous cell carcinoma [32,33]. These reports
suggested that THBS1 played diverse roles in the tumori-
genesis. Possible mechanism is that there are two tempo-
rally distinct phases to the effect of THBS1 on cancer
progression. During the early stage, THBS1 inhibits neo-
vascularization and holds tumor growth. In latter stage,
THBS1 may function as an adhesive protein or a modula-
tor of extracellular proteases to promote tumor invasion
[34]. Indeed, in our study, THBS1 was overexpressed and
correlated with regional lymph node invasion in ESCC
and, interestingly, patients with two or more of THBS1,
Cyr61 and CTGF over-expressions had significantly
shorter survival. Therefore, we postulated that overexpres-
sion of THBS1 might lead to more interaction with LTBP
in the upstream of TGF-β pathway contributing to the acti-
vation of TGF-β signaling pathway in ESCC.
In conclusion, we showed here, three TGF-β-related genes
(CTGF, CYR61 and THBS1) were over-expressed in ESCC.
THBS1, Cyr61 and CTGF might be significant diagnostic
markers for ESCC. More importantly, Cyr61 and CTGF
could serve as independent prognostic markers for ESCC.
Further studies will be needed to establish the biological
Table 2: Multivariate Cox regression analysis by Cyr61 expression levels
Variable Hazard ratio 95% confidence interval P
Regional lymph node 1.194 0.173–8.240 0.858
Primary tumor 1.346 0.352–5.137 0.664
Histologic grade 0.484 0.215–1.093 0.081
TNM Stage 1.504 0.459–4.926 0.500
Cyr61 overexpressor 5.347 1.374–20.816 0.016*
￿ Significant at P < 0.05 level
Table 3: Multivariate Cox regression analysis by CTGF expression levels
Variable Hazard ratio 95% confidence interval P
Regional lymph node 1.694 0.347–8.279 0.515
Primary tumor 3.839 1.016–14.506 0.047*
Histologic grade 1.418 0.556–3.616 0.464
TNM Stage 1.091 0.384–3.098 0.871
CTGF overexpressor 27.099 3.535–207.728 0.001*
* Significant at P < 0.05 level.BMC Cancer 2009, 9:291 http://www.biomedcentral.com/1471-2407/9/291
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significance of THBS1, Cyr61 or CTGF expression and to
examine the possibility as therapeutic targets in ESCC.
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